Wall Street analysts forecast that Celsion Co. (NASDAQ:CLSN – Get Rating) will post sales of $110,000.00 for the current fiscal quarter, according to Zacks. Three analysts have issued estimates for Celsion’s earnings. The lowest sales estimate is $100,000.00 and the highest is $130,000.00. Celsion posted sales of $130,000.00 during the same quarter last year, which would indicate a negative year-over-year growth rate of 15.4%. The company is scheduled to report its next quarterly earnings report on Monday, January 1st.
On average, analysts expect that Celsion will report full-year sales of $500,000.00 for the current financial year. For the next fiscal year, analysts anticipate that the business will report sales of $500,000.00. Zacks Investment Research’s sales averages are a mean average based on a survey of analysts that cover Celsion.
Celsion (NASDAQ:CLSN – Get Rating) last posted its earnings results on Monday, May 16th. The biotechnology company reported ($1.82) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.99) by ($0.83). Celsion had a negative return on equity of 45.34% and a negative net margin of 5,110.80%. During the same quarter in the prior year, the company earned ($1.35) earnings per share.
NASDAQ:CLSN traded down $0.01 during mid-day trading on Thursday, hitting $2.36. 64,837 shares of the stock traded hands, compared to its average volume of 219,875. Celsion has a 52 week low of $2.23 and a 52 week high of $23.25. The firm’s 50 day moving average is $3.65 and its two-hundred day moving average is $6.44. The company has a debt-to-equity ratio of 0.13, a quick ratio of 7.67 and a current ratio of 6.60.
A number of institutional investors have recently added to or reduced their stakes in the business. Jane Street Group LLC boosted its position in Celsion by 181.8% in the 3rd quarter. Jane Street Group LLC now owns 36,055 shares of the biotechnology company’s stock valued at $33,000 after buying an additional 23,261 shares during the period. Geode Capital Management LLC boosted its position in Celsion by 7.8% in the 3rd quarter. Geode Capital Management LLC now owns 756,885 shares of the biotechnology company’s stock valued at $699,000 after buying an additional 54,785 shares during the period. FNY Investment Advisers LLC purchased a new stake in Celsion in the 4th quarter valued at about $35,000. Two Sigma Advisers LP purchased a new stake in Celsion in the 3rd quarter valued at about $68,000. Finally, Virtu Financial LLC purchased a new stake in Celsion in the 4th quarter valued at about $55,000.
Celsion Company Profile (Get Rating)
Celsion Corporation, a clinical stage biotechnology company, focuses on the development and commercialization of DNA-based immunotherapies, vaccines, and directed chemotherapies. Its product pipeline includes GEN-1, a DNA-based immunotherapy for the localized treatment of ovarian cancer; and ThermoDox, a proprietary heat-activated liposomal encapsulation of doxorubicin, which is in development stage for various cancer indications.
- Get a free copy of the StockNews.com research report on Celsion (CLSN)
- Genesco Pops On Earnings But Don’t Expect A Rally
- The Insiders Are Selling Movado Group, But You Shouldn’t
- Beware The Rebound In Retail Stocks
- It’s A Good Time To Own Ralph Lauren (NYSE: RL)
- Block, Inc: Correcting for Negative Earnings
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Celsion Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celsion and related companies with MarketBeat.com's FREE daily email newsletter.